Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial. Issue 3 (18th January 2015)

• Record Type: Journal Article
• Authors: Kim, M. K.; Rhee, E.‐J.; Han, K. A.; Woo, A. C.; Lee, M.‐K.; Ku, B. J.; Chung, C. H.; Kim, K.‐A.; Lee, H. W.; Park, I. B.; Park, J. Y.; Chul Jang, H. C.; Park, K. S.; Jang, W. I.; Cha, B. Y.
• Is Part Of: Diabetes, obesity & metabolism. Volume 17:Issue 3(2015:Mar.)
• Page Start: 309
• Page End: 312
• Publication Date: 2015-01-18
• Subjects: Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12424
• Languages: English
• ISSNs: 1462-8902

Abstract

<abstract abstract-type="main" id="dom12424-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <p id="dom12424-para-0001">The aim of the present study was to assess the efficacy and safety of teneligliptin in combination with metformin in Korean patients with type 2 diabetes mellitus who were inadequately controlled with metformin monotherapy. Patients [glycated haemoglobin (HbA1c) 7.0–10.0%, on stable metformin ≥1000 mg/day] were randomized 2 : 1 to receive 20 mg teneligliptin plus metformin (<italic>n</italic> = 136) or placebo plus metformin (<italic>n</italic> = 68). The primary endpoint was the change in HbA1c levels from baseline to week 16. The mean baseline HbA1c was 7.9% in the teneligliptin group and 7.8% in the placebo group. The differences between the teneligliptin and placebo groups regarding changes in HbA1c and fasting plasma glucose levels were −0.78 % and −1.24 mmol/l (22.42 mg/dl), respectively, at week 16. The incidence of adverse events was similar between the groups. The addition of teneligliptin once daily to metformin was effective and generally well tolerated in Korean patients with type 2 diabetes.</p> </abstract>